Pradip Shah, MD
Infectious Disease · Edison, NJNPI 1437175155
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,347 of the $13,436 with a category attached, or 69.6%. 37 manufacturers reported payments, led by Shionogi Inc at 28.5% of the total. Reporting peaked in 2024 at $5,268 and has fallen 78.2% since, to $1,146 in 2025. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 374 payments — averaging $35.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$4K
- Viiv Healthcare Company$1K
- Gilead$1K
- Johnson & Johnson$862
- Merck$780
- Boehringer Ingelheim$758
- plus $4K from 31 others
What the payments were for
- Consulting fees$3,88829%
- Food & beverage$9,34770%
- Education$2022%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 4 | $3,833 |
| Viiv Healthcare Company | 73 | $1,489 |
| Gilead | 79 | $1,262 |
| Johnson & Johnson(2 entities) | 32 | $862 |
| Merck | 55 | $780 |
| Boehringer Ingelheim | 7 | $758 |
| Insmed, Inc. | 25 | $573 |
| Novo Nordisk | 11 | $568 |
| GSK | 4 | $500 |
| Novartis | 16 | $449 |
| AstraZeneca | 2 | $250 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $250 |
| Sanofi-aventis U.S. LLC | 2 | $250 |
| Lilly USA, LLC | 11 | $215 |
| Janssen Products, LP | 2 | $189 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 1 | $125 |
| Lexicon Pharmaceuticals, Inc. | 1 | $125 |
| Comsort, Inc | 1 | $100 |
| Pfizer | 6 | $92 |
| Abbott | 1 | $78 |
| Avanir Pharmaceuticals, Inc. | 5 | $72 |
| Boston Scientific | 1 | $72 |
| La Jolla Pharmaceutical Company | 3 | $64 |
| Melinta Therapeutics, LLC | 4 | $58 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $51 |
| Paratek Pharmaceuticals, Inc. | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Nabriva Therapeutics, PLC | 2 | $27 |
| AbbVie | 2 | $27 |
| Cumberland Pharmaceuticals, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| QOL Medical, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,436 in reported general payments places this provider in the 90th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 63 | $239,070 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 59 | $212,012 |
| Isentress HdRaltegravir Potassium | 38 | $74,852 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $56,198 |
| DescovyEmtricitabine/Tenofov Alafenam | 26 | $55,928 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 13 | $53,017 |
| EliquisApixaban | 102 | $43,702 |
| XifaxanRifaximin | 18 | $23,433 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 18 | $17,653 |
| JardianceEmpagliflozin | 15 | $10,735 |
| OzempicSemaglutide | 11 | $10,715 |
| TradjentaLinagliptin | 28 | $10,234 |
| MyrbetriqMirabegron | 24 | $6,052 |
| EntrestoSacubitril/Valsartan | 15 | $4,680 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 12 | $3,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Stribild | $1,262 | $348,015102 claims |
| Viiv Healthcare CompanyTriumeq | $1,489 | $212,01259 claims |
| MerckIsentress Hd | $780 | $74,85238 claims |
| Janssen Products, LPSymtuza | $189 | $56,19812 claims |
| PfizerEliquis | $92 | $43,702102 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $250 | $23,43318 claims |
| Boehringer IngelheimJardiance, Tradjenta | $758 | $20,96943 claims |
| Novo NordiskOzempic | $568 | $10,71511 claims |
| NovartisEntresto | $449 | $4,68015 claims |
| Lilly USA, LLCHumalog | $215 | $1,34020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Edison
- Adeel ButtEdison$10K
- Keith GottesdienerRahway$2.1M
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Ronald NahassHillsborough$213K
- Christopher LucastiSomers Point$112K
- Spartaco BellomoJersey City$111K
- Jack BoghossianBayonne$97K
- Adriana GrigoriuJersey City$89K
- Sukrut DwivediOakhurst$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.